Pseudoprogression on bevacizumab treatment: tumor-dynamics in the modern era of systemic treatment for metastatic colorectal cancer

For several years, it is known that classic RECIST criteria are suboptimal to evaluate cancer treatment with targeted and immunomodulatory agents, for instance because these criteria underestimate ...